The A-List: The Trend-Shaping Series A Financings Of 2012
This article was originally published in Start Up
Executive Summary
There’s still money for early-stage innovation despite worries to the contrary, but total dollars for Series A financings remain about one-third fewer than during the high years of the mid-2000s, and investor syndicates are mindful of making those dollars stretch as far as possible. For the 2012 A-List, our ninth, we’ve decided to ask a fundamental question as the life science venture world goes through economic upheaval: does “Series A” mean the same thing, or conjure the same connotations, as it did when the class of 2004 made the first A-List?
You may also be interested in...
venBio Rings In 2013 With Two Company Launches
New venture firm venBio, which closed its inaugural $200 million fund in 2010, has begun the new year by unveiling two start ups with very different business propositions.
In Cartilage Repair Histogenics Resets The Stage
In July Histogenics Corp. raised $49 million in a Series A recap round that will help it complete a Phase III clinical trial in articular cartilage repair. The deal also shows that Histogenics’ novel strategy for getting through the mid-stage funding gap was a success.
In HIV Research, A Race For The Cure Is Back On Track
Hopes for a vaccine or cure for HIV/AIDS have been dashed before. But recent scientific advances and greater understanding of the limits of antiretroviral drugs have reignited optimism. Just don't expect VCs to get on board.